BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...until 2014. Since then, Goupit has served on the boards of Inventiva S.A. (NASDAQ:IVA; Euronext:IVA) and MedDay S.A....
BioCentury | Jan 17, 2020
Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

...prodrug company Ascendis Pharma A/S (NASDAQ:ASND); CNS-focused gene therapy company Lysogene S.A. (Euronext:LYS); neurodegeneration play MedDay S.A....
BioCentury | Nov 5, 2016
Finance

Vive la biotech

...Antoine Papiernik, Bpifrance’s Laurent Higueret and Nobécourt think portfolio company MedDay S.A. could become a bellwether. MedDay...
...York, N.Y. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. MedDay S.A....
...Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. GamaMabs Pharma S.A. Genfit S.A. GenSight Biologics S.A. Innate Pharma S.A. MedDay S.A. Enyo...
BioCentury | Apr 11, 2016
Financial News

MedDay completes venture financing

MedDay S.A. , Paris, France Business: Neurology Date completed: 2016-04-08 Type: Venture financing Raised: EUR34 million ($38.7 million) Investors: Edmond de Rothschild Investment Partners; Sofinnova Partners; InnoBio Fund; Bpifrance WIR Staff Neurology...
BioCentury | Apr 9, 2016
Financial News

MedDay raises EUR 34M in series B

...another Phase III study in the indication (see BioCentury Extra, April 17, 2015). Sedal said MedDay...
...of D-biotin that targets a rate-limiting enzyme in myelination. Edmond de Rothschild's Raphael Wisniewski joined MedDay's...
BioCentury | Dec 7, 2015
Clinical News

MD1003: Phase III data

...vs. a worsening of 1.5 letters and an improvement of 3 letters, respectively, for placebo. Medday...
...trial to treat primary or secondary progressive MS (see BioCentury, April 27 & Aug. 3). Medday...
BioCentury | Sep 29, 2015
Clinical News

Roche's ocrelizumab meets in Phase III PPMS trial

...amended in 2010. One other company has reported positive data for progressive MS. In April, Medday...
BioCentury | Aug 17, 2015
Strategy

Shifting MS spending

...progressive MS is mitoxantrone, a generic chemotherapeutic inhibitor of DNA replication. Frédéric Sedel, CEO of Medday...
...enzyme in myelination. It is in Phase III testing to treat progressive forms of MS. Medday...
...Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Harvard Pilgrim Health Care Inc., Boston, Mass. Medday...
BioCentury | Aug 3, 2015
Clinical News

MD1003: Additional Phase III data

...of 4.5-7 points. Data were presented at the European Academy of Neurology meeting in Berlin. Medday...
...a confirmation at 12 months, vs. placebo (12.6% vs. 0%, p=0.0051) (see BioCentury, April 27). Medday...
...trial of MD1003 in MS patients with permanent visual loss following optic neuritis this year. Medday...
BioCentury | Apr 27, 2015
Clinical News

MD1003: Phase III data

...progression at 9 months confirmed at 12 months vs. 13% of patients receiving placebo (p=0.07). Medday...
...meeting in Washington, D.C. There are no approved drugs in the U.S. for progressive MS. Medday...
...FDA and EMA for MD1003 in parallel after it reports data from the second trial. Medday...
Items per page:
1 - 10 of 14
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...until 2014. Since then, Goupit has served on the boards of Inventiva S.A. (NASDAQ:IVA; Euronext:IVA) and MedDay S.A....
BioCentury | Jan 17, 2020
Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

...prodrug company Ascendis Pharma A/S (NASDAQ:ASND); CNS-focused gene therapy company Lysogene S.A. (Euronext:LYS); neurodegeneration play MedDay S.A....
BioCentury | Nov 5, 2016
Finance

Vive la biotech

...Antoine Papiernik, Bpifrance’s Laurent Higueret and Nobécourt think portfolio company MedDay S.A. could become a bellwether. MedDay...
...York, N.Y. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. MedDay S.A....
...Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. GamaMabs Pharma S.A. Genfit S.A. GenSight Biologics S.A. Innate Pharma S.A. MedDay S.A. Enyo...
BioCentury | Apr 11, 2016
Financial News

MedDay completes venture financing

MedDay S.A. , Paris, France Business: Neurology Date completed: 2016-04-08 Type: Venture financing Raised: EUR34 million ($38.7 million) Investors: Edmond de Rothschild Investment Partners; Sofinnova Partners; InnoBio Fund; Bpifrance WIR Staff Neurology...
BioCentury | Apr 9, 2016
Financial News

MedDay raises EUR 34M in series B

...another Phase III study in the indication (see BioCentury Extra, April 17, 2015). Sedal said MedDay...
...of D-biotin that targets a rate-limiting enzyme in myelination. Edmond de Rothschild's Raphael Wisniewski joined MedDay's...
BioCentury | Dec 7, 2015
Clinical News

MD1003: Phase III data

...vs. a worsening of 1.5 letters and an improvement of 3 letters, respectively, for placebo. Medday...
...trial to treat primary or secondary progressive MS (see BioCentury, April 27 & Aug. 3). Medday...
BioCentury | Sep 29, 2015
Clinical News

Roche's ocrelizumab meets in Phase III PPMS trial

...amended in 2010. One other company has reported positive data for progressive MS. In April, Medday...
BioCentury | Aug 17, 2015
Strategy

Shifting MS spending

...progressive MS is mitoxantrone, a generic chemotherapeutic inhibitor of DNA replication. Frédéric Sedel, CEO of Medday...
...enzyme in myelination. It is in Phase III testing to treat progressive forms of MS. Medday...
...Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Harvard Pilgrim Health Care Inc., Boston, Mass. Medday...
BioCentury | Aug 3, 2015
Clinical News

MD1003: Additional Phase III data

...of 4.5-7 points. Data were presented at the European Academy of Neurology meeting in Berlin. Medday...
...a confirmation at 12 months, vs. placebo (12.6% vs. 0%, p=0.0051) (see BioCentury, April 27). Medday...
...trial of MD1003 in MS patients with permanent visual loss following optic neuritis this year. Medday...
BioCentury | Apr 27, 2015
Clinical News

MD1003: Phase III data

...progression at 9 months confirmed at 12 months vs. 13% of patients receiving placebo (p=0.07). Medday...
...meeting in Washington, D.C. There are no approved drugs in the U.S. for progressive MS. Medday...
...FDA and EMA for MD1003 in parallel after it reports data from the second trial. Medday...
Items per page:
1 - 10 of 14